FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека пептидов

Cagrilintide

NN9838

Weight Loss & Metabolic

Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk, designed to mimic the satiety-inducing effects of the naturally occurring hormone amylin. It is administered as a once-weekly subcutaneous injection and is currently in Phase 3 clinical trials. Cagrilintide is a key component of the combination therapy CagriSema, paired with semaglutide for enhanced weight loss.

Механизм действия

Long-acting amylin analog that slows gastric emptying, promotes satiety, and reduces postprandial glucagon secretion. Works synergistically with GLP-1 agonists.

Протоколы исследований

Только для исследовательских целей. Не медицинская консультация.

Research protocols use 1.2mg to 4.5mg weekly. Dose escalation over 16 weeks. Often studied in combination with semaglutide.

Примечания к исследованиям

Clinical Research Status

Cagrilintide is in Phase 3 development as both a standalone agent and as part of the CagriSema combination with semaglutide. The REDEFINE Phase 2 trial demonstrated dose-dependent weight loss of up to 10.8% over 26 weeks as monotherapy. Novo Nordisk is positioning it primarily as a combination component rather than pursuing standalone approval initially.

Key Published Findings

Phase 2 data showed cagrilintide 4.5mg weekly produced significantly greater weight loss than placebo, with a distinct mechanism from GLP-1 agonists acting through amylin pathways. Amylin analogs slow gastric emptying, reduce glucagon secretion, and promote satiety through area postrema signaling. The combination with semaglutide showed additive effects beyond either agent alone in early trials.

Safety Profile

The most common adverse effects are gastrointestinal, including nausea and decreased appetite, consistent with amylin receptor activation. Injection site reactions have been reported but are generally mild and transient. Long-term safety data is still accumulating as Phase 3 trials continue, with particular attention to pancreatic safety signals.

Comparison to Related Compounds

Unlike pramlintide (Symlin), which requires three-times-daily dosing, cagrilintide's acylation technology enables once-weekly administration. It works through a complementary mechanism to GLP-1 agonists, targeting amylin rather than incretin pathways. The combination approach with semaglutide represents a multi-receptor strategy similar in concept to tirzepatide's dual GIP/GLP-1 action but using a physically separate co-formulation.

Community Observations

Research interest in cagrilintide centers primarily on its role within CagriSema rather than as a standalone compound. The amylin mechanism is understood to primarily enhance early meal satiety, complementing GLP-1's effects on sustained fullness. Clinical trial participants have reported that the combination produces qualitatively different appetite suppression compared to GLP-1 monotherapy.

Половая жизнь

~7-10 days

Реконституция

Bacteriostatic water (BAC)

Хранение

Лиофилизированный

Refrigerate 2-8C. Protect from light.

Реконститутированный

Refrigerate 2-8C. Use within 28 days.

Юридический статус США

Research chemical (not FDA-approved)

Также известен как

NN9838

Часто задаваемые вопросы

Что такое Cagrilintide?

Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk, designed to mimic the satiety-inducing effects of the naturally occurring hormone amylin. It is administered as a once-weekly subcutaneous injection and is currently in Phase 3 clinical trials. Cagrilintide is a key component of the combination therapy CagriSema, paired with semaglutide for enhanced weight loss.

Как действует Cagrilintide?

Long-acting amylin analog that slows gastric emptying, promotes satiety, and reduces postprandial glucagon secretion. Works synergistically with GLP-1 agonists.

Каков регуляторный статус Cagrilintide в США?

Research chemical (not FDA-approved)

Каков период полувыведения Cagrilintide?

~7-10 days

Как ещё называют Cagrilintide?

NN9838

Peptide Contacts предоставляет исследовательские сводки только для информационных целей. Мы не хостим, распространяем или одобряем документацию поставщиков. Все сертификаты анализа, GMP-сертификаты и коммуникации с поставщиками должны быть запрослены и проверены непосредственно покупателем. Ничто на этом платформе не является юридическим, медицинским или профессиональным советом. Пользователи самостоятельно отвечают за проверку квалификаций поставщиков и обеспечение соответствия всем применимым местным, штатным и федеральным законам перед покупкой любых исследовательских химикатов. Использование этой платформы означает принятие полной личной ответственности.

Прочитать полное заявление о неприкосновенности